RBC Capital Reiterates Outperform Rating on Bio-Rad Labs (BIO)
Tweet Send to a Friend
RBC Capital analyst Dan Leonard reiterated an Outperform rating and $390.00 price target on Bio-Rad Labs (NYSE: BIO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


